Berman Tabacco Investigates Potential Securities Claims Against Zymergen Inc. (ZY)

Boston, Massachusetts--(Newsfile Corp. - August 4, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations against Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY), a "biofacturing" company with headquarters in Emeryville, California.

In April 2021, the Company completed its initial public offering ("IPO"). In the IPO, the Company sold approximately 18.5 million common shares at $31 per share.

On August 3, 2021, after the market close, the Company issued a press release announcing that it "recently became aware of issues with its commercial product pipeline that will impact the Company's delivery timeline and revenue projections." As a result, the Company stated that it "no longer expects product revenue in 2021." The press release also announced that the Company's Chief Executive Officer ("CEO") would "step down as CEO and as a member of the Board, effective immediately."

In response to this news, shares of Zymergen were down over 75%, to as low as $7.85 per share, in early trading on August 4, 2021.

If you purchased Zymergen securities in the IPO or on the open market between April 22, 2021 and August 3, 2021, and would like more information regarding this investigation, or if you wish simply to share information about the investigation, please visit: https://www.bermantabacco.com/case/zymergen/.

Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California. This notice may constitute attorney advertising.

Contact:
Jay Eng, Esq.
(800) 516-9926
Email: law@bermantabacco.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92087